NEW YORK, April 24 - Amersham Biosciences, which filed for an initial public offering as APBiotech in October 2000, withdrew its offering from the SEC yesterday, citing the company's recent acquisition by Amersham. In February last year, after several delays, the company had set a price of $15-$17 per share for 18,200,000 shares of common stock and said it would use the cash for "general corporate purposes, primarily to fund our operations and to pay indebtedness."
In March Amersham said it planned to buy Pharmacia's 45 percent stake in Amersham Biosciences for £704 million, or roughly $992 million.
At the time of its filing, Amersham listed as its competitors: PE Biosystems, Packard BioScience, Affymetrix, the
Micromass division of Waters, Aurora Biosciences, and Third Wave Technologies.